Q4 2020 13F Holders as of 12/31/2020
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
19.3M
-
Number of holders
-
226
-
Total 13F shares, excl. options
-
22.4M
-
Shares change
-
-77.2K
-
Total reported value, excl. options
-
$2.22B
-
Value change
-
-$5.88M
-
Put/Call ratio
-
2.76
-
Number of buys
-
97
-
Number of sells
-
-130
-
Price
-
$99.45
Significant Holders of LIGAND PHARMACEUTICALS INC - Common Stock (LGND) as of Q4 2020
287 filings reported holding LGND - LIGAND PHARMACEUTICALS INC - Common Stock as of Q4 2020.
LIGAND PHARMACEUTICALS INC - Common Stock (LGND) has 226 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 22.4M shares
.
Largest 10 shareholders include WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC (2.04M shares), BlackRock Inc. (1.97M shares), JANUS HENDERSON GROUP PLC (1.61M shares), VANGUARD GROUP INC (1.46M shares), WASATCH ADVISORS INC (1.17M shares), STATE STREET CORP (1.17M shares), CARDINAL CAPITAL MANAGEMENT LLC /CT (1.09M shares), MACQUARIE GROUP LTD (895K shares), Conestoga Capital Advisors, LLC (716K shares), and VILLERE ST DENIS J & CO LLC (642K shares).
This table shows the top 226 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.